Ketchum John B 4

What Happened John B. Ketchum, a director of Tango Therapeutics, received equity compensation on June 5, 2026: 4,000 restricted stock units (RSUs) and a derivative award of 25,000 shares (reported as an option-like award). Both awards are recorded at $0.00 per share in the Form 4 (i.e., these were grants/awards rather than open-market purchases or sales).

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (timely filing).
• Awards: 4,000 RSUs and a 25,000-share derivative award (option), reported at $0.00 per share.
• Vesting: RSUs (4,000) vest in full on the earlier of June 5, 2027 or the next annual meeting, subject to continuous service (Footnote F1). The 25,000-share option vests in 12 substantially equal monthly installments over one year, with the first vesting on July 5, 2026 (Footnote F2).
• Shares owned after transaction: not specified in this filing.
• Exhibit included: Exhibit 24 (Power of Attorney).

Context

• RSUs represent a contingent right to receive shares upon vesting; they do not represent immediate share ownership until settled (per footnote F1). The 25,000-share award is an option-style grant that becomes exercisable as it vests (per footnote F2).
• These entries are compensation grants (neutral to slightly bullish signals insofar as management/board ownership increases over time) and are not sales or purchases in the open market.